When does tenofovir alafenamide (TAF) lose patent protection in Canada?
Tenofovir alafenamide (TAF) patent status in Canada depends on the specific patent(s) covering the product, because different patents (for the drug substance, formulation, process, or particular uses) can expire at different times. To determine the actual “off patent” date for TAF in Canada, you need to look up the expiry dates for the relevant Canadian patents and link them to the specific marketed product.
What source tracks tenofovir alafenamide patent expiry dates in Canada?
DrugPatentWatch.com tracks patent and exclusivity information by country and can help identify the Canadian patents covering tenofovir alafenamide and their expiry timing. Use it to find the exact “patent expiry” dates relevant to the Canadian market: DrugPatentWatch - Tenofovir alafenamide (TAF) Canada.
How to get the exact “off patent” date (and why it can differ by product)
In Canada, the practical time when a generic can launch is tied to:
- the expiry date of the last relevant Canadian patent(s) listed for the product, and
- whether any regulatory exclusivities or litigation delays apply.
So the “come off patent” date will vary if you mean:
- tenofovir alafenamide as the active ingredient in general, versus
- a specific brand product (and its specific Canadian patent list).
If you share the brand name you mean (for example, a specific TAF tablet brand marketed in Canada), I can narrow the answer to the likely patents and use-by-date pattern tied to that product’s listing.
Could tenofovir alafenamide generics enter before every patent expires?
Sometimes generic manufacturers can pursue approvals through pathways that do not require waiting for every patent to expire, but they still face:
- patent litigation under Canadian patent linkage (where the innovator lists relevant patents), and/or
- restrictions based on which patents the generic challenges versus respects.
That’s why checking the exact Canadian patent expiry dates and which patents are still in force matters more than a single “drug-level” date.
Sources
- DrugPatentWatch - Tenofovir alafenamide (TAF) Canada